Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

Inclusion Criteria: Patients with metastatic colorectal cancer (confirmed histologically) with objective response or stabilization after at least 6 cycles of first line chemotherapy (treatment of choice is selected freely by the investigator according to the recommendations and consensus in force), The interval between completion of first line chemotherapy and randomization should not exceed 4 weeks Age>18 years ECOG status 0 to 2 Biological criteria prior to any chemotherapy: Neutrophils>1.5 109 g/l, platelets>100 109/l, haemoglobin>10 g/dl, Creatininaemia<150 mol/l, bilirubinaemia<2x normal level Signed informed consent Life expectancy > 3 months Exclusion Criteria: Metastatic colorectal cancer treated with more than one modality of first line chemotherapy (including oral fluoropyrimidines) Tumour progression after first line chemotherapy or before randomization Other tumour pathology Symptomatic cerebral metastases Any severe uncontrolled disease in addition to colorectal cancer (in particular decompensated cardiac failure (LVEF<50%) or coronary insufficiency) Lack of integrity of the upper GI tract: malabsorption syndrome or major surgery of the stomach or the small intestine Severe renal impairment (creatinine clearance < 30 ml/min) Severe psychiatric disorder (other than controlled depressive syndrome) Patient participating in another experiment Pregnant women